All In Biotech

Drug Trial Radar · NCT03328026

Combination Study of SV-BR-1-GM With Retifanlimab

A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Mar 16, 2018

Primary completion

Mar 24, 2026

Study completion Mar 24, 2026

Sponsor

Sponsor type
Industry
Collaborators
LumaBridge
First posted
Nov 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination with retifanlimab in patients with metastatic or locally recurrent breast cancer who have failed standard therapy. Patients will receive the SV-BR-1-GM regimen with combination immunotherapy. There will be an initial evaluation of the combination of the SV-BR-1-GM regimen with retifanlimab every 3 weeks. If this is found to be safe and well tolerated in a cohort of at least 12 patients (dose-limiting toxicities (DLTs) in less than 30% of the patients evaluated), then an expansion cohort of up to 24 patients will be treated with that combination. These will be randomized to two regimens differing in the timing of checkpoint inhibitor administration.

Conditions

  • Breast Cancer
  • Breast Neoplasm
  • Metastatic Breast Cancer
  • Breast Cancer Metastatic

Interventions

  • SV-BR-1-GMBiological

    SV-BR-1-GM inoculation intradermally at 4 sites.

  • Low dose cyclophosphamideDrug

    Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.

  • Interferon InoculationDrug

    Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.

  • retifanlimabDrug

    retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the Adverse Events (AEs), including Serious Adverse Events (SAEs), that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab) [Safety]Time frame: Through study completion, an average of 1 year
  2. Evaluate the Proportion of Patients with Abnormalities in Safety Laboratory Parameters that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab) [Safety]Time frame: Through study completion, an average of 1 year
  3. Evaluate changes in the electrocardiogram QT interval that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab)[Safety]Time frame: Through study completion, an average of 1 year

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • St. Joseph Heritage Healthcare

    Santa Rosa, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University of Miami/Sylvester at Plantation

    Plantation, Florida

  • Carle Cancer Institute

    Urbana, Illinois

  • Cancer Center of Kansas (CCK)

    Wichita, Kansas

  • The Center for Cancer and Blood Disorders a division of American Oncology Partners MD

    Bethesda, Maryland

  • St Vincent-Frontier Cancer Center

    Billings, Montana

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Overlook Medical Center Oncology Research, Atlantic Health System

    Summit, New Jersey

  • Manhattan Hematology Oncology Associates (MHOA)

    Manhattan, New York

  • Mary Crowley Cancer Research

    Dallas, Texas

  • Tranquil Clinical Research

    Webster, Texas

  • Hematology-Oncology Associates of Fredericksburg, Inc

    Fredericksburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.